Main Menu (Mobile)- Block

Main Menu - Block

A proliferative to invasive switch is mediated by srGAP1 downregulation through the activation of TGF-β2 signaling.

Our Research / Publications
janelia7_blocks-janelia7_biblio_header | block
Cell Reports. 2022 Sep 20;40(12):111358. doi: 10.1016/j.celrep.2022.111358
View Article on
A proliferative to invasive switch is mediated by srGAP1 downregulation through the activation of TGF-β2 signaling. Betzig Lab
Mondal C, Gacha-Garay MJ, Larkin KA, Adikes RC, Di Martino JS, Chien C, Fraser M, Eni-Aganga I, Agullo-Pascual E, Cialowicz K, Ozbek U, Naba A, Gaitas A, Fu T, Upadhyayula S, Betzig E, Matus DQ, Martin BL, Bravo-Cordero JJ
janelia7_blocks-janelia7_biblio_abstract | block

Abstract

Many breast cancer (BC) patients suffer from complications of metastatic disease. To form metastases, cancer cells must become migratory and coordinate both invasive and proliferative programs at distant organs. Here, we identify srGAP1 as a regulator of a proliferative-to-invasive switch in BC cells. High-resolution light-sheet microscopy demonstrates that BC cells can form actin-rich protrusions during extravasation. srGAP1 cells display a motile and invasive phenotype that facilitates their extravasation from blood vessels, as shown in zebrafish and mouse models, while attenuating tumor growth. Interestingly, a population of srGAP1 cells remain as solitary disseminated tumor cells in the lungs of mice bearing BC tumors. Overall, srGAP1 cells have increased Smad2 activation and TGF-β2 secretion, resulting in increased invasion and p27 levels to sustain quiescence. These findings identify srGAP1 as a mediator of a proliferative to invasive phenotypic switch in BC cells in vivo through a TGF-β2-mediated signaling axis.

PMID: 36130489 [PubMed - indexed for MEDLINE]

janelia7_blocks-janelia7_biblio_authors | block

Janelia Authors

Tian-Ming Fu
Eric Betzig
janelia7_blocks-janelia7_biblio_tools | block